Molecure Reports First Patient Dosing with OATD-01 Under the P-II (KITE) Trial to Treat Pulmonary Sarcoidosis
Shots:
- Molecure has dosed the first patient with OATD-01 under its P-II clinical evaluation for active pulmonary sarcoidosis across the UK
- The P-II (KITE) study assesses the safety and efficacy of OATD-01 (25mg, oral, QD, 12wks.) vs PBO for the treatment of active pulmonary sarcoidosis patients (n=100) who are both treatment-naïve and have received other therapies across the US, the EU, Norway & the UK
- OATD-01 is a selective candidate that inhibits CHIT1 which results in anti-inflammatory and anti-fibrotic effects by blocking the conversion of anti-inflammatory macrophages into pro-inflammatory and pro-fibrotic types
Ref: Molecure | Image: Molecure
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
